HIV chemokine receptor inhibitors as novel anti-HIV drugs

Cytokine and Growth Factor Reviews

Volumn 16, Issue 6, 2005, Pages 659-677

  Princen, Katrien ^a   Schols, Dominique ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Antagonist; CCR5; Chemokine receptor; CXCR4; HIV

Indexed keywords

1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); 4 [(4 BROMOPHENYL)(ETHOXYIMINO)METHYL] 1' [(2,4 DIMETHYL 3 PYRIDINYL)CARBONYL] 4' METHYL 1,4' BIPIPERIDINE; ALPHA N ACETYLNONA DEXTRO ARGININE AMIDE; AMD 070; AMD 1498; AMD 1657; AMD 2763; AMD 3451; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; APLAVIROC; BICYCLAM; CHEMOKINE; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; KRH 1636; MARAVIROC; N (6 AMINOHEXYL)GLYCYL N (3 GUANIDINOPROPYL)GLYCYL N (3 GUANIDINOPROPYL)GLYCYL N BENZYLGLYCYL N (3 GUANIDINOPROPYL)GLYCYL DEXTRO LYSYL DEXTRO LYSYL DEXTRO ARGINYL DEXTRO PROLINAMIDE; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; PRO 140; RANTES; STROMAL CELL DERIVED FACTOR 1; T 140; T 22; UNCLASSIFIED DRUG; VICRIVIROC;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; T LYMPHOCYTE; VIRUS INHIBITION; VIRUS MORPHOLOGY; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 27144465704     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2005.05.009     Document Type: Article

References (154)

1. F. Barre-Sinoussi, J.C. Chermann, F. Rey, M.T. Nugeyre, S. Chamaret, and J. Gruest Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS) Science 220 1983 868 871
2. J.C. Chermann, F. Barre-Sinoussi, C. Dauguet, F. Brun-Vezinet, C. Rouzioux, and W. Rozenbaum Isolation of a new retrovirus in a patient at risk for acquired immunodeficiency syndrome Antibiot Chemother 32 1983 48 53
3. R.J. Pomerantz, and D.L. Horn Twenty years of therapy for HIV-1 infection Nat Med 9 2003 867 873
4. D.J. Hu, T.J. Dondero, M.A. Rayfield, J.R. George, G. Schochetman, and H.W. Jaffe The emerging genetic diversity of HIV. The importance of global surveillance for diagnostics, research, and prevention JAMA 275 1996 210 216
5. R. De Leys, B. Vanderborght, M. Vanden Haesevelde, L. Heyndrickx, A. van Geel, and C. Wauters Isolation and partial characterization of an unusual human immunodeficiency retrovirus from two persons of West-central African origin J Virol 64 1990 1207 1216
6. J. Erickson Virology HIV resistance and implications for therapy 1998 Medicom Inc Atlanta
7. R.A. Weiss Gulliver's travels in HIVland Nature 410 2001 963 967
8. J.N. Blankson, D. Persaud, and R.F. Siliciano The challenge of viral reservoirs in HIV-1 infection Annu Rev Med 53 2002 557 593
9. T.W. Chun, and A.S. Fauci Latent reservoirs of HIV: obstacles to the eradication of virus Proc Natl Acad Sci USA 96 1999 10958 10961
10. S. Aquaro, R. Calio, J. Balzarini, M.C. Bellocchi, E. Garaci, and C.F. Perno Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir Antiviral Res 55 2002 209 225
11. D.D. Richman HIV chemotherapy Nature 410 2001 995 1001
12. X. Wei, J.M. Decker, H. Liu, Z. Zhang, R.B. Arani, and J.M. Kilby Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy Antimicrob Agents Chemother 46 2002 1896 1905
13. B.J. Doranz, J.F. Berson, J. Rucker, and R.W. Doms Chemokine receptors as fusion cofactors for human immunodeficiency virus type 1 (HIV-1) Immunol Res 16 1997 15 28
14. Y. Feng, C.C. Broder, P.E. Kennedy, and E.A. Berger HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor Science 272 1996 872 877
15. G. Alkhatib, C. Combadiere, C.C. Broder, Y. Feng, P.E. Kennedy, and P.M. Murphy CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1 Science 272 1996 1955 1958
16. H. Deng, R. Liu, W. Ellmeier, S. Choe, D. Unutmaz, and M. Burkhart Identification of a major co-receptor for primary isolates of HIV-1 Nature 381 1996 661 666
17. T. Dragic, V. Litwin, G.P. Allaway, S.R. Martin, Y. Huang, and K.A. Nagashima HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5 Nature 381 1996 667 673
18. + T cells Science 270 1995 1811 1815
19. M. Samson, F. Libert, B.J. Doranz, J. Rucker, C. Liesnard, and C.M. Farber Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene Nature 382 1996 722 725
20. R. Liu, W.A. Paxton, S. Choe, D. Ceradini, S.R. Martin, and R. Horuk Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection Cell 86 1996 367 377
21. M. Dean, M. Carrington, C. Winkler, G.A. Huttley, M.W. Smith, and R. Allikmets Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study Science 273 1996 1856 1862
22. M. Baggiolini Chemokines and leukocyte traffic Nature 392 1998 565 568
23. P.M. Murphy International Union of Pharmacology. XXX. Update on chemokine receptor nomenclature Pharmacol Rev 54 2002 227 229
24. T.S. Olson, and K. Ley Chemokines and chemokine receptors in leukocyte trafficking Am J Physiol Regul Integr Comp Physiol 283 2002 R7 R28
25. P.J. Lodi, D.S. Garrett, J. Kuszewski, M.L. Tsang, J.A. Weatherbee, and W.J. Leonard High-resolution solution structure of the beta chemokine hMIP-1 beta by multidimensional NMR Science 263 1994 1762 1767
26. R. Horuk, C.E. Chitnis, W.C. Darbonne, T.J. Colby, A. Rybicki, and T.J. Hadley A receptor for the malarial parasite Plasmodium vivax: the erythrocyte chemokine receptor Science 261 1993 1182 1184
27. R.J. Nibbs, S.M. Wylie, J. Yang, N.R. Landau, and G.J. Graham Cloning and characterization of a novel promiscuous human beta-chemokine receptor D6 J Biol Chem 272 1997 32078 32083
28. J.R. Townson, and R.J. Nibbs Characterization of mouse CCX-CKR, a receptor for the lymphocyte-attracting chemokines TECK/mCCL25, SLC/mCCL21 and MIP-3beta/mCCL19: comparison to human CCX-CKR Eur J Immunol 32 2002 1230 1241
29. A.D. Luster, S.M. Greenberg, and P. Leder The IP-10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation J Exp Med 182 1995 219 231
30. A. Rot Endothelial cell binding of NAP-1/IL-8: role in neutrophil emigration Immunol Today 13 1992 291 294
31. G.S. Kuschert, F. Coulin, C.A. Power, A.E. Proudfoot, R.E. Hubbard, and A.J. Hoogewerf Glycosaminoglycans interact selectively with chemokines and modulate receptor binding and cellular responses Biochemistry 38 1999 12959 12968
32. A.J. Hoogewerf, G.S. Kuschert, A.E. Proudfoot, F. Borlat, I. Clark-Lewis, and C.A. Power Glycosaminoglycans mediate cell surface oligomerization of chemokines Biochemistry 36 1997 13570 13578
33. A.G. Dalgleish, P.C. Beverley, P.R. Clapham, D.H. Crawford, M.F. Greaves, and R.A. Weiss The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus Nature 312 1984 763 767
34. D. Klatzmann, E. Champagne, S. Chamaret, J. Gruest, D. Guetard, and T. Hercend T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV Nature 312 1984 767 768
35. P.J. Maddon, A.G. Dalgleish, J.S. McDougal, P.R. Clapham, R.A. Weiss, and R. Axel The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain Cell 47 1986 333 348
36. P.R. Clapham, D. Blanc, and R.A. Weiss Specific cell surface requirements for the infection of CD4-positive cells by human immunodeficiency virus types 1 and 2 and by Simian immunodeficiency virus Virology 181 1991 703 715
37. T. Dragic, P. Charneau, F. Clavel, and M. Alizon Complementation of murine cells for human immunodeficiency virus envelope/CD4-mediated fusion in human/murine heterokaryons J Virol 66 1992 4794 4802
38. W. James, R.A. Weiss, and J.H. Simon The receptor for HIV: dissection of CD4 and studies on putative accessory factors Curr Top Microbiol Immunol 205 1996 137 158
39. E.A. Berger, P.M. Murphy, and J.M. Farber Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease Ann Rev Immunol 17 1999 657 700
40. D.R. Littman Chemokine receptors: keys to AIDS pathogenesis? Cell 93 1998 677 680
41. F. Miedema, L. Meyaard, M. Koot, M.R. Klein, M.T. Roos, and M. Groenink Changing virus-host interactions in the course of HIV-1 infection Immunol Rev 140 1994 35 72
42. J.F. Berson, D. Long, B.J. Doranz, J. Rucker, F.R. Jirik, and R.W. Doms A seven-transmembrane domain receptor involved in fusion and entry of T-cell-tropic human immunodeficiency virus type 1 strains J Virol 70 1996 6288 6295
43. C. Combadiere, S.K. Ahuja, H.L. Tiffany, and P.M. Murphy Cloning and functional expression of CC CKR5, a human monocyte CC chemokine receptor selective for MIP-1(alpha), MIP-1(beta), and RANTES J Leukocyte Biol 60 1996 147 152
44. M. Samson, O. Labbe, C. Mollereau, G. Vassart, and M. Parmentier Molecular cloning and functional expression of a new human CC-chemokine receptor gene Biochemistry 35 1996 3362 3367
45. H. Choe, M. Farzan, Y. Sun, N. Sullivan, B. Rollins, and P.D. Ponath The β-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates Cell 85 1996 1135 1148
46. C.C. Bleul, M. Farzan, H. Choe, C. Parolin, I. Clark-Lewis, and J. Sodroski The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry Nature 382 1996 829 833
47. E. Oberlin, A. Amara, F. Bachelerie, C. Bessia, J.L. Virelizier, and F. Arenzana-Seisdedos The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1 Nature 382 1996 833 835
48. Q.J. Sattentau HIV gp120: double lock strategy foils host defences Structure 6 1998 945 949
49. T.B. Geijtenbeek, D.S. Kwon, R. Torensma, S.J. van Vliet, G.C. van Duijnhoven, and J. Middel DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells Cell 100 2000 587 597
50. S.G. Turville, J. Arthos, K.M. Donald, G. Lynch, H. Naif, and G. Clark HIV gp120 receptors on human dendritic cells Blood 98 2001 2482 2488
51. A. Trkola, T. Dragic, J. Arthos, J.M. Binley, W.C. Olson, and G.P. Allaway CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5 Nature 384 1996 184 187
52. L. Wu, N.P. Gerard, R. Wyatt, H. Choe, C. Parolin, and N. Ruffing CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5 Nature 384 1996 179 183
53. T.L. Hoffman, C.C. LaBranche, W. Zhang, G. Canziani, J. Robinson, and I. Chaiken Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein Proc Natl Acad Sci USA 96 1999 6359 6364
54. F. Cocchi, A.L. DeVico, A. Garzino-Demo, A. Cara, R.C. Gallo, and P. Lusso The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection Nat Med 2 1996 1244 1247
55. W. Weissenhorn, A. Dessen, S.C. Harrison, J.J. Skehel, and D.C. Wiley Atomic structure of the ectodomain from HIV-1 gp41 Nature 387 1997 426 430
56. R. Barbouche, R. Miquelis, I.M. Jones, and E. Fenouillet Protein-disulfide isomerase-mediated reduction of two disulfide bonds of HIV envelope glycoprotein 120 occurs post-CXCR4 binding and is required for fusion J Biol Chem 278 2003 3131 3136
57. R.W. Doms Beyond receptor expression: the influence of receptor conformation, density, and affinity in HIV-1 infection Virology 276 2000 229 237
58. G. Stent, G.B. Joo, P. Kierulf, and B. Asjo Macrophage tropism: fact or fiction? J Leukocyte Biol 62 1997 4 11
59. Y. Yi, S.N. Isaacs, D.A. Williams, I. Frank, D. Schols, and E. De Clercq Role of CXCR4 in cell-cell fusion and infection of monocyte-derived macrophages by primary human immunodeficiency virus type 1 (HIV-1) strains: two distinct mechanisms of HIV-1 dual tropism J Virol 73 1999 7117 7125
60. T.B. Kristiansen, T.B. Knudsen, and J. Eugen-Olsen Chemokine receptors and their crucial role in human immunodeficiency virus infection: major breakthroughs in HIV research Scand J Immunol 48 1998 339 346
61. E. De Clercq, and D. Schols Inhibition of HIV infection by CXCR4 and CCR5 chemokine receptor antagonists Antiviral Chem Chemother 12 2001 19 31
62. A. Jekle, B. Schramm, P. Jayakumar, V. Trautner, D. Schols, and E. De Clercq Coreceptor phenotype of natural human immunodeficiency virus with nef deleted evolves in vivo, leading to increased virulence J Virol 76 2002 6966 6973
63. A. Jekle, O.T. Keppler, E. De Clercq, D. Schols, M. Weinstein, and M.A. Goldsmith In vivo evolution of human immunodeficiency virus type 1 toward increased pathogenicity through CXCR4-mediated killing of uninfected CD4 T cells J Virol 77 2003 5846 5854
64. + T cell depletion in HIV-1-infected human lymphoid tissue Proc Natl Acad Sci USA 96 1999 663 668
65. G. Scarlatti, E. Tresoldi, A. Bjorndal, R. Fredriksson, C. Colognesi, and H.K. Deng In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression Nat Med 3 1997 1259 1265
66. J.W. Mellors, C.R. Rinaldo Jr., P. Gupta, R.M. White, J.A. Todd, and L.A. Kingsley Prognosis in HIV-1 infection predicted by the quantity of virus in plasma Science 272 1996 1167 1170
67. D.R. Henrard, E. Daar, H. Farzadegan, S.J. Clark, J. Phillips, and G.M. Shaw Virologic and immunologic characterization of symptomatic and asymptomatic primary HIV-1 infection J Acquir Immune Defic Syndr Hum Retrovirol 9 1995 305 310
68. D.D. Ho, A.U. Neumann, A.S. Perelson, W. Chen, J.M. Leonard, and M. Markowitz Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection Nature 373 1995 123 126
69. R.I. Connor, K.E. Sheridan, D. Ceradini, S. Choe, and N.R. Landau Change in coreceptor use coreceptor use correlates with disease progression in HIV-1-infected individuals J Exp Med 185 1997 621 628
70. J.A. Este, C. Cabrera, J. Blanco, A. Gutierrez, G. Bridger, and G. Henson Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and prevention of emergence of the syncytium-inducing phenotype by blockade of CXCR4 J Virol 73 1999 5577 5585
71. S. Glushakova, Y. Yi, J.C. Grivel, A. Singh, D. Schols, and E. De Clercq Preferential coreceptor utilization and cytopathicity by dual-tropic HIV-1 in human lymphoid tissue ex vivo J Clin Invest 104 1999 R7 R11
72. H. Schuitemaker, M. Koot, N.A. Kootstra, M.W. Dercksen, R.E. de Goede, and R.P. van Steenwijk Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population J Virol 66 1992 1354 1360
73. R.A. Fouchier, M. Groenink, N.A. Kootstra, M. Tersmette, H.G. Huisman, and F. Miedema Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule J Virol 66 1992 3183 3187
74. R.A. Fouchier, M. Brouwer, S.M. Broersen, and H. Schuitemaker Simple determination of human immunodeficiency virus type 1 syncytium-inducing V3 genotype by PCR J Clin Microbiol 33 1995 906 911
75. M.A. Jensen, and A.B. 't Wout Predicting HIV-1 coreceptor usage with sequence analysis AIDS Rev 5 2003 104 112
76. A. Bjorndal, H. Deng, M. Jansson, J.R. Fiore, C. Colognesi, and A. Karlsson Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype J Virol 71 1997 7478 7487
77. G. Lin, F. Baribaud, J. Romano, R.W. Doms, and J.A. Hoxie Identification of gp120 binding sites on CXCR4 by using CD4-independent human immunodeficiency virus type 2 Env proteins J Virol 77 2003 931 942
78. Q.X. Hu, A.P. Barry, Z.X. Wang, S.M. Connolly, S.C. Peiper, and M.L. Greenberg Evolution of the human immunodeficiency virus type 1 envelope during infection reveals molecular corollaries of specificity for coreceptor utilization and AIDS pathogenesis J Virol 74 2000 11858 11872
79. A. Amara, S.L. Gall, O. Schwartz, J. Salamero, M. Montes, and P. Loetscher HIV coreceptor downregulation as antiviral principle: SDF-1alpha-dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of HIV replication J Exp Med 186 1997 139 146
80. M. Mack, B. Luckow, P.J. Nelson, J. Cihak, G. Simmons, and P.R. Clapham Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity J Exp Med 187 1998 1215 1224
81. V. Marechal, F. Arenzana-Seisdedos, J.M. Heard, and O. Schwartz Opposite effects of SDF-1 on human immunodeficiency virus type 1 replication J Virol 73 1999 3608 3615
82. A. Garzino-Demo, A.L. DeVico, F. Cocchi, and R.C. Gallo β-chemokines and protection from HIV type 1 disease AIDS Res Hum Retrovir 14 1998 S177 S184
83. W.A. Paxton, S.R. Martin, D. Tse, T.R. O'Brien, J. Skurnick, and N.L. VanDevanter Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure Nat Med 2 1996 412 417
84. C.J. Gordon, M.A. Muesing, A.E. Proudfoot, C.A. Power, J.P. Moore, and A. Trkola Enhancement of human immunodeficiency virus type 1 infection by the CC-chemokine RANTES is independent of the mechanism of virus-cell fusion J Virol 73 1999 684 694
85. M.D. Kelly, H.M. Naif, S.L. Adams, A.L. Cunningham, and A.R. Lloyd Dichotomous effects of beta-chemokines on HIV replication in monocytes and monocyte-derived macrophages J Immunol 160 1998 3091 3095
86. A.J. Marozsan, V.S. Torre, M. Johnson, S.C. Ball, J.V. Cross, and D.J. Templeton Mechanisms involved in stimulation of human immunodeficiency virus type 1 replication by aminooxypentane RANTES J Virol 75 2001 8624 8638
87. D.E. Mosier, G.R. Picchio, R.J. Gulizia, R. Sabbe, P. Poignard, and L. Picard Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants J Virol 73 1999 3544 3550
88. A. Trkola, C. Gordon, J. Matthews, E. Maxwell, T. Ketas, and L. Czaplewski The CC-chemokine RANTES increases the attachment of human immunodeficiency virus type 1 to target cells via glycosaminoglycans and also activates a signal transduction pathway that enhances viral infectivity J Virol 73 1999 6370 6379
89. P. Garred, J. Eugen-Olsen, A.K. Iversen, T.L. Benfield, A. Svejgaard, and B. Hofmann Dual effect of CCR5 Δ32 gene deletion in HIV-1-infected patients. Copenhagen AIDS Study Group Lancet 349 1997 1884
90. N.L. Michael, J.A. Nelson, V.N. KewalRamani, G. Chang, S.J. O'Brien, and J.R. Mascola Exclusive and persistent use of the entry coreceptor CXCR4 by human immunodeficiency virus type 1 from a subject homozygous for CCR5 Δ32 J Virol 72 1998 6040 6047
91. E. Gonzalez, H. Kulkarni, H. Bolivar, A. Mangano, R. Sanchez, and G. Catano The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility Science 307 2005 1434 1440
92. Q. Ma, D. Jones, P.R. Borghesani, R.A. Segal, T. Nagasawa, and T. Kishimoto Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice Proc Natl Acad Sci USA 95 1998 9448 9453
93. T. Nagasawa, S. Hirota, K. Tachibana, N. Takakura, S. Nishikawa, and Y. Kitamura Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1 Nature 382 1996 635 638
94. Y.R. Zou, A.H. Kottmann, M. Kuroda, I. Taniuchi, and D.R. Littman Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development Nature 393 1998 595 599
95. P. Menten, S. Struyf, E. Schutyser, A. Wuyts, E. De Clercq, and D. Schols The LD78β isoform of MIP-1α is the most potent CCR5 agonist and HIV-1-inhibiting chemokine J Clin Invest 104 1999 R1 R5
96. S. Aquaro, P. Menten, S. Struyf, P. Proost, J. Van Damme, and E. De Clercq The LD78β isoform of MIP-1α is the most potent CC-chemokine in inhibiting CCR5-dependent human immunodeficiency virus type 1 replication in human macrophages J Virol 75 2001 4402 4406
97. I. De Meester, S. Korom, J. Van Damme, and S. Scharpe CD26, let it cut or cut it down Immunol Today 20 1999 367 375
98. D. Schols, P. Proost, S. Struyf, A. Wuyts, M.I. De, and S. Scharpe CD26-processed RANTES(3-68), but not intact RANTES, has potent anti-HIV-1 activity Antiviral Res 39 1998 175 187
99. P. Proost, M.I. De, D. Schols, S. Struyf, A.M. Lambeir, and A. Wuyts Amino-terminal truncation of chemokines by CD26/dipeptidyl-peptidase. IV. Conversion of RANTES into a potent inhibitor of monocyte chemotaxis and HIV-1-infection J Biol Chem 273 1998 7222 7227
100. F. Arenzana-Seisdedos, J.L. Virelizier, D. Rousset, I. Clark-Lewis, P. Loetscher, and B. Moser HIV blocked by chemokine antagonist Nature 383 1996 400
101. G. Simmons, P.R. Clapham, L. Picard, R.E. Offord, M.M. Rosenkilde, and T.W. Schwartz Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist Science 276 1997 276 279
102. A.E. Proudfoot, C.A. Power, A.J. Hoogewerf, M.O. Montjovent, F. Borlat, and R.E. Offord Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist J Biol Chem 271 1996 2599 2603
103. M.M. Lederman, R.S. Veazey, R. Offord, D.E. Mosier, J. Dufour, and M. Mefford Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5 Science 306 2004 485 487
104. J.R. Townson, G.J. Graham, N.R. Landau, B. Rasala, and R.J. Nibbs Aminooxypentane addition to the chemokine macrophage inflammatory protein-1alpha P increases receptor affinities and HIV inhibition J Biol Chem 275 2000 39254 39261
105. O.O. Yang, S.L. Swanberg, Z. Lu, M. Dziejman, J. McCoy, and A.D. Luster Enhanced inhibition of human immunodeficiency virus type 1 by Met-stromal-derived factor 1beta correlates with down-modulation of CXCR4 J Virol 73 1999 4582 4589
106. E. De Clercq, N. Yamamoto, R. Pauwels, M. Baba, D. Schols, and H. Nakashima Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event Proc Natl Acad Sci USA 89 1992 5286 5290
107. E. De Clercq The bicyclam AMD3100 story Nat Rev Drug Discov 2 2003 581 587
108. E. De Clercq, N. Yamamoto, R. Pauwels, J. Balzarini, M. Witvrouw, and K. De Vreese Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100 Antimicrob Agents Chemother 38 1994 668 674
109. G.J. Bridger, R.T. Skerlj, D. Thornton, S. Padmanabhan, S.A. Martellucci, and G.W. Henson Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-tetraazamacrocycles that inhibit HIV replication. Effects of macrocyclic ring size and substituents on the aromatic linker J Med Chem 38 1995 366 378
110. H.C. Joao, K. De Vreese, R. Pauwels, E. De Clercq, G.W. Henson, and G.J. Bridger Quantitative structural activity relationship study of bis-tetraazacyclic compounds. A novel series of HIV-1 and HIV-2 inhibitors J Med Chem 38 1995 3865 3873
111. K. De Vreese, V. Kofler-Mongold, C. Leutgeb, V. Weber, K. Vermeire, and S. Schacht The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication J Virol 70 1996 689 696
112. K. De Vreese, N.I. Van, K. Vermeire, J. Anne, and E. De Clercq Sensitivity of human immunodeficiency virus to bicyclam derivatives is influenced by the three-dimensional structure of gp120 Antimicrob Agents Chemother 41 1997 2616 2620
113. J.A. Este, K. De Vreese, M. Witvrouw, J.C. Schmit, A.M. VanDamme, and J. Anne Antiviral activity of the bicyclam derivative JM3100 against drug-resistant strains of human immunodeficiency virus type 1 Antiviral Res 29 1996 297 307
114. D. Schols, J.A. Este, G. Henson, and E. De Clercq Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4 Antiviral Res 35 1997 147 156
115. D. Schols, S. Struyf, J. Van Damme, J.A. Este, G. Henson, and E. De Clercq Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4 J Exp Med 186 1997 1383 1388
116. G.A. Donzella, D. Schols, S.W. Lin, J.A. Este, K.A. Nagashima, and P.J. Maddon AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor Nat Med 4 1998 72 77
117. B. Schramm, M.L. Penn, R.F. Speck, S.Y. Chan, E. De Clercq, and D. Schols Viral entry through CXCR4 is a pathogenic factor and therapeutic target in human immunodeficiency virus type 1 disease J Virol 74 2000 184 192
118. S. Hatse, K. Princen, G. Bridger, E. De Clercq, and D. Schols Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4 FEBS Lett 527 2002 255 262
119. C.W. Hendrix, C. Flexner, R.T. MacFarland, C. Giandomenico, E.J. Fuchs, and E. Redpath Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers Antimicrob Agents Chemother 44 2000 1667 1673
120. C.W. Hendrix, A.C. Collier, M.M. Lederman, D. Schols, R.B. Pollard, and S. Brown Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection J Acquir Immune Defic Syndr 37 2004 1253 1262
121. T. Murakami, T. Nakajima, Y. Koyanagi, K. Tachibana, N. Fujii, and H. Tamamura A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection J Exp Med 186 1997 1389 1393
122. R. Arakaki, H. Tamamura, M. Premanathan, K. Kanbara, S. Ramanan, and K. Mochizuki T134, a small-molecule CXCR4 inhibitor, has no cross-drug resistance with AMD3100, a CXCR4 antagonist with a different structure J Virol 73 1999 1719 1723
123. H. Tamamura, Y. Xu, T. Hattori, X. Zhang, R. Arakaki, and K. Kanbara A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140 Biochem Biophys Res Com 253 1998 877 882
124. B.J. Doranz, K. Grovit-Ferbas, M.P. Sharron, S.H. Mao, M.B. Goetz, and E.S. Daar A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor J Exp Med 186 1997 1395 1400
125. M. Sumner-Smith, Y. Zheng, Y.P. Zhang, E.M. Twist, and S.C. Climie Antiherpetic activities of N-alpha-acetyl-nona-d-arginine amide acetate Drugs Exp Clin Res 21 1995 1 6
126. B.J. Doranz, L.G. Filion, F. Diaz-Mitoma, D.S. Sitar, J. Sahai, and F. Baribaud Safe use of the CXCR4 inhibitor ALX40-4C in humans AIDS Res Hum Retrovir 17 2001 475 486
127. N. Zhou, J. Fang, E. Acheampong, M. Mukhtar, and R.J. Pomerantz Binding of ALX40-4C to APJ, a CNS-based receptor, inhibits its utilization as a co-receptor by HIV-1 Virology 312 2003 196 203
128. D. Daelemans, D. Schols, M. Witvrouw, C. Pannecouque, S. Hatse, and S. van Dooren A second target for the peptoid Tat/transactivation response element inhibitor CGP64222: inhibition of human immunodeficiency virus replication by blocking CXC-chemokine receptor 4-mediated virus entry Mol Pharmacol 57 2000 116 124
129. F. Hamy, E.R. Felder, G. Heizmann, J. Lazdins, F. Aboul-ela, and G. Varani An inhibitor of the Tat/TAR RNA interaction that effectively suppresses HIV-1 replication Proc Natl Acad Sci USA 94 1997 3548 3553
130. K. Ichiyama, S. Yokoyama-Kumakura, Y. Tanaka, R. Tanaka, K. Hirose, and K. Bannai A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activity Proc Natl Acad Sci USA 100 2003 4185 4190
131. D. Schols, S. Claes, S. Hatse, K. Princen, K. Vermeire, and E. De Clercq Anti-HIV activity profile of AMD070, an orally bioavailable CXCR4 antagonist Proceedings of the 10th conference on retroviruses and opportunistic infections Boston, USA 2003 [Abstract book, p. 257]
132. K. Princen, S. Hatse, K. Vermeire, S. Aquaro, E. De Clercq, and L.O. Gerlach Inhibition of human immunodeficiency virus replication by a dual CCR5/CXCR4 antagonist J Virol 78 2004 12996 13006
133. M. Baba, O. Nishimura, N. Kanzaki, M. Okamoto, H. Sawada, and Y. Iizawa A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity Proc Natl Acad Sci USA 96 1999 5698 5703
134. T. Dragic, A. Trkola, D.A. Thompson, E.G. Cormier, F.A. Kajumo, and E. Maxwell A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5 Proc Natl Acad Sci USA 97 2000 5639 5644
135. J.M. Strizki, S. Xu, N.E. Wagner, L. Wojcik, J. Liu, and Y. Hou SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo Proc Natl Acad Sci USA 98 2001 12718 12723
136. J. Reynes, R. Rouzier, T. Kanouni, V. Baillat, B. Baroudy, and A. Keung SCH C: Safety and antiviral effects of a CCR5 receptor antagonist in HIV-1 infected subjects Proceedings of the Ninth conference on retroviruses and opportunistic infections Seattle, USA 2002 [Abstract book, p. 53]
137. D. Schurmann, R. Rouzier, R. Nougarede, J. Reynes, G. Fatkenheuer, and F. Raffi SCH-D: Antiviral activity of CCR5 receptor antagonist Proceedings of the 11th conference on retroviruses and opportunistic infections San Fransisco, USA 2004 [Abstract book, p. 128]
138. K. Maeda, K. Yoshimura, S. Shibayama, H. Habashita, H. Tada, and K. Sagawa Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5 J Biol Chem 276 2001 35194 35200
139. K. Maeda, H. Nakata, T. Miyakawa, H. Ogata, Y. Koh, and S. Shibayama AK602: a novel HIV-specific spirodiketopiperazine CCR5 inhibitor potent against a wide spectrum of R5-HIV Proceedings of the 10th conference on retroviruses and opportunistic infections Boston, USA 2003 [Abstract book, p. 61]
140. C. Napier, P. Dorr, R. Gladue, R. Halliday, D. Leishman, and I. Machin The preclinical pharmacokinetics and safety pharmacology of the anti-HIV CCR5 antagonist, UK-427857 Proceedings of the 10th conference on retroviruses and opportunistic infections Boston, USA 2003 [Abstract book, p. 251]
141. A. Trkola, T.J. Ketas, K.A. Nagashima, L. Zhao, T. Cilliers, and L. Morris Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140 J Virol 75 2001 579 588
142. M. Franti, L. Ramos, S. Maloveste, D. Geerdes, K.A. Nagashima, and T. Ketas Control of HIV-1 replication in the hu-PBL-SCID mouse model by an anti-CCR5 monoclonal antibody Proceedings of the 11th conference on retroviruses and opportunistic infections San Francisco, USA 2004 [Abstract book, p. 257]
143. D. Schols, S. Claes, E. De Clercq, C. Hendrix, G. Bridger, and G. Calandra AMD-3100, a CXCR4 antagonist, reduced HIV viral load and X4 virus levels in humans Proceedings of the 9th conference on retroviruses and opportunistic infections Seattle, USA 2002 [Abstract book, p. 53]
144. H. Nakata, K. Maeda, Y. Kawano, T. Miyakawa, S. Shibayama, and M. Matsuo Potent in vivo anti-R5-HIV effects of AK602, a novel spirodiketopiperazine (SDP)-containing HIV-specific CCR5 inhibitor, in hu-PBMC-NOD-SCID Mice Proceedings of the 10th conference on retroviruses and opportunistic infections Boston, USA 2003 [Abstract book, p. 258]
145. B.J. Doranz, J. Rucker, Y. Yi, R.J. Smyth, M. Samson, and S.C. Peiper A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors Cell 85 1996 1149 1158
146. A. Jinno, N. Shimizu, Y. Soda, Y. Haraguchi, T. Kitamura, and H. Hoshino Identification of the chemokine receptor TER1/CCR8 expressed in brain-derived cells and T cells as a new coreceptor for HIV-1 infection Biochem Biophys Res Commun 243 1998 497 502
147. R. Horuk, J. Hesselgesser, Y. Zhou, D. Faulds, M. Halks-Miller, and S. Harvey The CC chemokine I-309 inhibits CCR8-dependent infection by diverse HIV-1 strains J Biol Chem 273 1998 386 391
148. H. Choe, M. Farzan, M. Konkel, K. Martin, Y. Sun, and L. Marcon The orphan seven-transmembrane receptor apj supports the entry of primary T-cell-line-tropic and dualtropic human immunodeficiency virus type 1 J Virol 72 1998 6113 6118
149. C. Combadiere, K. Salzwedel, E.D. Smith, H.L. Tiffany, E.A. Berger, and P.M. Murphy Identification of CX3CR1. A chemotactic receptor for the human CX3C chemokine fractalkine and a fusion coreceptor for HIV-1 J Biol Chem 273 1998 23799 23804
150. F. Liao, G. Alkhatib, K.W. Peden, G. Sharma, E.A. Berger, and J.M. Farber STRL33, a novel chemokine receptor-like protein, functions as a fusion cofactor for both macrophage-tropic and T cell line-tropic HIV-1 J Exp Med 185 1997 2015 2023
151. M. Matloubian, A. David, S. Engel, J.E. Ryan, and J.G. Cyster A transmembrane CXC chemokine is a ligand for HIV-coreceptor Bonzo Nat Immunol 1 2000 298 304
152. A.L. Edinger, T.L. Hoffman, M. Sharron, B. Lee, Y. Yi, and W. Choe An orphan seven-transmembrane domain receptor expressed widely in the brain functions as a coreceptor for human immunodeficiency virus type 1 and simian immunodeficiency virus J Virol 72 1998 7934 7940
153. H.K. Deng, D. Unutmaz, V.N. KewalRamani, and D.R. Littman Expression cloning of new receptors used by simian and human immunodeficiency viruses Nature 388 1997 296 300
154. M. Heiber, A. Marchese, T. Nguyen, H.H. Heng, S.R. George, and B.F. O'Dowd A novel human gene encoding a G-protein-coupled receptor (GPR15) is located on chromosome 3 Genomics 32 1996 462 465